Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.25 4.00 4.50 4.50 4.25 4.25 389,627 14:37:54
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.1 -2.7 - 6

Evgen Pharma Share Discussion Threads

Showing 1526 to 1549 of 1900 messages
Chat Pages: Latest  64  63  62  61  60  59  58  57  56  55  54  53  Older
DateSubjectAuthorDiscuss
28/8/2019
22:31
Even better for us then. Nimodipine was the last approved drug for SAH 30yrs ago, with making just marginal improvement to patients. Any significant improvement for patients using SFX-01 will be transformational.
90005nelson
28/8/2019
22:17
there are other results due..Sept.
babbler
28/8/2019
20:38
Too much emphasis on the sellers, when it's the first piece of liquidity since the last placing. Timeline is early October around six weeks away, which is a long time on AIM but that gives plenty of opportunities to add to one's position, if wanted. As we get nearer to the results the share price will rise in anticipation.
90005nelson
28/8/2019
18:54
I agree - the RNS was not full of any great drama or fanfare (nor should they be IMO), but I am struggling to see what justified any drop at all to be honest. AIM is a funny old place. I might be tempted to have another small top up if this drops back to circa 15p, but the wiser decision might just be to sit tight and await full results...
lovewinshatelosses
28/8/2019
15:39
which part were they not impressed with?
zed2002
28/8/2019
14:41
Market has not been very impressed with the RNS IMO
buywell3
28/8/2019
13:39
Bloody crazy drop due to impatience.
babbler
28/8/2019
08:44
These will have a big run to the SAH results.
hsm12
27/8/2019
16:38
👍👍
nobbygnome
27/8/2019
16:27
Hi everyone, Just a little update to say I’m still on sfx01 next see my Onco on 11th September, that’s 452 days on this. Hoping for good results for SAH. 😀😀
blakeysangel
27/8/2019
13:41
I've bought back in, hopefully,I've timed it right this time!!
crapcrap
23/8/2019
19:54
Oh dear we have a troll, willywonka. In case you are not aware the next trial result is in SAH. Go and google SAH to find out what it is. They have already got a positive phase II breast cancer result so difficult to see how in the short to medium term there can be any effect of a breast cancer trial result as there isn't one ongoing! You don't half get some muppets on these threads....
nobbygnome
23/8/2019
19:07
"Following discussions with our clinicians and statistical advisers, we have decided to unblind the SAS trial's primary and secondary endpoint data at the same time.... This approach will maximise the commercial value of the dataset from the SAS trial."They can sell SFX-01 after the results are released, through orphan drug status.
90005nelson
23/8/2019
19:02
Nobody investing in this type of small cap company is unaware of the potential risk of eventual total capital losses in the event of complete failure as a worst case scenario. I am curious as to whether posts like yours ever have a material impact on the share price - but either way, if things go as holders hope, the rewards for the risks we take as early investors will likely be satisfactory. We shall see soon enough, for good or bad.
lovewinshatelosses
23/8/2019
18:20
This has a high risk of failure esp for breast cancer Be prepared for 70/80% drop if trials dnt go to plan
willywonka22
23/8/2019
14:23
https://twitter.com/hashtag/EVG?src=hashtag_click
ohisay
23/8/2019
14:13
Find out soon. Gla
tidy 2
23/8/2019
14:09
Game on. Been tipped here
tidy 2
16/8/2019
19:26
Phase II trial of SFX-01 in SAH scheduled for completion next month (September 2019) hxxps://clinicaltrials.gov/ct2/show/record/NCT02614742 Results will shortly follow
asat91
15/8/2019
09:19
Another use for SFX-01 would appear to be mTOR inhibition; "The isothiocyanate sulforaphane inhibits mTOR in an NRF2-independent manner" hTTps://www.sciencedirect.com/science/article/pii/S0944711319302284?via%3Dihub One of the authors is Dinkova who is on the scientific board of Evgen. mTOR inhibition is of interest in Cancer and Neurogenerative disease.
pdt
08/8/2019
13:06
Interesting new article on Stroke and NRF2 from University of Florida; Nrf2 Plays an Essential Role in Long-Term Brain Damage and Neuroprotection of Korean Red Ginseng in a Permanent Cerebral Ischemia Model. hTTps://www.mdpi.com/2076-3921/8/8/273/htm
pdt
06/8/2019
19:19
https://twitter.com/AIMBAGGER1/status/1158816066816098305?s=19
90005nelson
06/8/2019
18:18
Good news the other day indeed, and seems to back up those thoughts hsm12. I would have expected a more positive market reaction, but no matter - I remain long and strong, as the saying goes.
lovewinshatelosses
06/8/2019
13:49
I missed the news yesterday of further research at Kings. Clearly Kings and the British Heart Foundation (providing most of the funding) see potential in SFX-01 for Stroke. From the release; Professor Giovanni Mann, Professor of Vascular Physiology at King's College London and supervisor for the project, commented: "We are delighted to be collaborating again with Evgen Pharma and believe this project will build on our existing collaboration which showed great promise for SFX-01 in both stroke and potentially wider neuropsychiatric complications."
pdt
Chat Pages: Latest  64  63  62  61  60  59  58  57  56  55  54  53  Older
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200229 06:40:23